Valeant Pharmaceuticals International Inc. (NYSE:VRX) had its price target decreased by Deutsche Bank AG from $30.00 to $29.00 in a research report report published on Friday morning. Deutsche Bank AG currently has a hold rating on the specialty pharmaceutical company’s stock.

VRX has been the topic of several other reports. Morgan Stanley reiterated a positive rating on shares of Valeant Pharmaceuticals International in a report on Friday, August 19th. Wells Fargo & Co. reiterated an underperform rating and issued a $19.50 target price on shares of Valeant Pharmaceuticals International in a report on Friday, September 30th. RBC Capital Markets set a $36.00 target price on Valeant Pharmaceuticals International and gave the company a hold rating in a report on Friday, August 19th. Royal Bank Of Canada reduced their target price on Valeant Pharmaceuticals International from $36.00 to $35.00 and set a sector perform rating on the stock in a report on Wednesday, October 12th. Finally, Jefferies Group reiterated a buy rating and issued a $40.00 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, August 10th. Six analysts have rated the stock with a sell rating, fifteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of Hold and an average price target of $56.45.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded down 1.80% on Friday, hitting $21.78. 4,894,581 shares of the stock traded hands. The stock’s market cap is $7.57 billion. The stock has a 50 day moving average of $26.60 and a 200-day moving average of $26.84. Valeant Pharmaceuticals International has a 1-year low of $18.55 and a 1-year high of $171.50.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 9.29% and a positive return on equity of 46.59%. The company earned $2.42 billion during the quarter, compared to the consensus estimate of $2.47 billion. During the same quarter in the previous year, the company earned $2.14 earnings per share. The business’s revenue was down 11.4% on a year-over-year basis. On average, equities research analysts expect that Valeant Pharmaceuticals International will post $6.53 EPS for the current year.

In other news, Director Argeris N. Karabelas acquired 4,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Thursday, August 11th. The stock was bought at an average price of $24.65 per share, for a total transaction of $98,600.00. Following the completion of the transaction, the director now owns 20,726 shares in the company, valued at $510,895.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 16.37% of the company’s stock.

A number of hedge funds have recently modified their holdings of VRX. Acrospire Investment Management LLC bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth approximately $108,000. Tower Research Capital LLC TRC boosted its stake in shares of Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 402 shares during the last quarter. Cacti Asset Management LLC boosted its stake in shares of Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock worth $169,000 after buying an additional 3,400 shares during the last quarter. AGF Investments Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 121.9% in the second quarter. AGF Investments Inc. now owns 8,842 shares of the specialty pharmaceutical company’s stock worth $178,000 after buying an additional 4,857 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth approximately $200,000. Institutional investors and hedge funds own 63.67% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.